IMRX

Immuneering Corporation

1.47 USD
+0.08 (+5.76%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Immuneering Corporation stock is down -0.68% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 May’s closed higher than April. 100% of analysts rate it a buy.

About Immuneering Corporation

Immuneering Corporation focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer.